Clinical Trial Detail

NCT ID NCT01386580
Title An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors to-BBB technologies B.V.
Indications

malignant glioma

lung cancer

breast cancer

brain cancer

Therapies

2B3-101

2B3-101 + Trastuzumab

Age Groups: adult senior

No variant requirements are available.